Neuropace, Inc. NPCE Deferred offering costs offset against additional paid-in capital
Deferred offering costs offset against additional paid-in capital at other companies
Other financials
Where this comes from
Reported directly by Neuropace, Inc. in its filing.
Tagged under the XBRL concept npce:DeferredOfferingCostsOffsetAgainstAdditionalPaidInCapital.
The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neuropace, Inc.'s deferred offering costs offset against additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neuropace, Inc.'s deferred offering costs offset against additional paid-in capital?
- Neuropace, Inc. (NPCE) reported deferred offering costs offset against additional paid-in capital of $0 in Q1 2026.
- How has Neuropace, Inc.'s deferred offering costs offset against additional paid-in capital changed year-over-year?
- Neuropace, Inc.'s deferred offering costs offset against additional paid-in capital decreased by 100.0% year-over-year, from $277K to $0.
- What does deferred offering costs offset against additional paid-in capital mean?
- This represents costs directly attributable to a capital-raising transaction, such as legal, accounting, and underwriting fees, that are netted against the proceeds in equity rather than expensed. Tracking these costs provides insight into the efficiency of the company's capital market activities. It helps investors understand the true cost of raising equity capital versus the net proceeds received.